Audio from Clinical Care Options: Zobair Younossi, MD, discusses the clinical impact of the most important NAFLD/NASH data from EASL 2019 in Vienna.
April 10-14, 2019; Vienna, Austria: Expert faculty members summarize key viral hepatitis studies from this important annual conference.
Phase II safety and efficacy data with thyroid hormone receptor beta agonist VK2809 vs placebo in NAFLD, from EASL 2019, as reported by Clinical Care Options (CCO).
EASL 2019 downloadable slideset: Phase II efficacy and safety results of emricasan, an oral caspase inhibitor, in NASH cirrhosis and severe portal HTN as reported by Clinical Care Options (CCO)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.